30J Stock Overview A synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
IDEAYA Biosciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for IDEAYA Biosciences Historical stock prices Current Share Price US$23.80 52 Week High US$44.40 52 Week Low US$23.80 Beta 0.80 1 Month Change -5.56% 3 Month Change -21.19% 1 Year Change -21.19% 3 Year Change 17.82% 5 Year Change 217.33% Change since IPO 286.99%
Recent News & Updates
IDEAYA Biosciences, Inc. Announces IDMCRecommendation of Move-Forward Dose in Part 2A of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma Dec 18 Ideaya Biosciences, Inc. Announces First-Patient-In for Phase 1 Clinical Trial Evaluating Ide161 in Combination with Keytruda®? (Pembrolizumab) in Patients with Endometrial Cancer
IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer Nov 18
New minor risk - Revenue size Nov 05
IDEAYA Biosciences, Inc. Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors Oct 28 IDEAYA Biosciences, Inc. Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 See more updates
IDEAYA Biosciences, Inc. Announces IDMCRecommendation of Move-Forward Dose in Part 2A of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma Dec 18 Ideaya Biosciences, Inc. Announces First-Patient-In for Phase 1 Clinical Trial Evaluating Ide161 in Combination with Keytruda®? (Pembrolizumab) in Patients with Endometrial Cancer
IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer Nov 18
New minor risk - Revenue size Nov 05
IDEAYA Biosciences, Inc. Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors Oct 28 IDEAYA Biosciences, Inc. Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024
IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel Sep 18
First half 2024 earnings released: US$1.21 loss per share (vs US$0.98 loss in 1H 2023) Aug 07 IDEAYA Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $263.000016 million.
IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 3000E Value Index Jul 03
IDEAYA Biosciences, Inc Announces Resignation of Jason Throne as Chief Legal Officer and Secretary, Effective July 11, 2024 Jun 27
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer Jun 25
IDEAYA Biosciences, Inc. Announces Clinical Program Updates for Ide397 A Potential First-In-Class Phase 2 Mat2a Inhibitor Targeting MTAP-Deletion Solid Tumors Jun 24
IDEAYA Biosciences, Inc. Announces Results for darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma At Asco and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study Jun 05
IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024 May 29
First quarter 2024 earnings released: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023) May 07
IDEAYA Biosciences, Inc., Annual General Meeting, May 31, 2024 Apr 21 IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer Mar 12
Full year 2023 earnings released: US$1.96 loss per share (vs US$1.42 loss in FY 2022) Feb 21
New major risk - Shareholder dilution Jan 24 IDEAYA Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $350 million. Jan 20
New major risk - Revenue and earnings growth Dec 05
Third quarter 2023 earnings released: US$0.46 loss per share (vs US$0.04 profit in 3Q 2022) Nov 09
IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline Oct 24
New minor risk - Share price stability Oct 16 IDEAYA Biosciences, Inc. Announces Resignation of Paul A. Stone as Chief Financial Officer
IDEAYA Biosciences, Inc. Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo) Adjuvant Uveal Melanoma Aug 17
New major risk - Revenue and earnings growth Aug 11
Second quarter 2023 earnings released: US$0.50 loss per share (vs US$0.57 loss in 2Q 2022) Aug 11
IDEAYA Biosciences, Inc. Appoints Andres Ruiz Briseno as Principal Accounting Officer Jul 06
New major risk - Shareholder dilution Jun 29
IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types Jun 13
First quarter 2023 earnings released: US$0.49 loss per share (vs US$0.36 loss in 1Q 2022) May 10
Full year 2022 earnings released: US$1.42 loss per share (vs US$1.41 loss in FY 2021) Mar 09
IDEAYA Biosciences, Inc. Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma Jan 24
IDEAYA Biosciences, Inc. Announces Board Appointments Dec 20
IDEAYA Biosciences, Inc Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161 Dec 13
IDEAYA Biosciences, Inc. Appoints Darrin M. Beaupre as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline Nov 29
Third quarter 2022 earnings released: EPS: US$0.04 (vs US$0.31 loss in 3Q 2021) Nov 09
IDEAYA Biosciences, Inc. Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors Oct 19
IDEAYA Biosciences, Inc. Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma Sep 12
IDEAYA Biosciences, Inc. Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma Sep 07
IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-In-Class Pol Theta Helicase Inhibitor Development Candidate Aug 30
Second quarter 2022 earnings released: US$0.57 loss per share (vs US$0.33 loss in 2Q 2021) Aug 16
IDEAYA Biosciences, Inc. Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors Jul 28
IDEAYA Biosciences, Inc. Announces Development Candidate Nomination of Potential First-In-Class Pol Theta Helicase Inhibitor in Collaboration with GSK Jun 29
IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 2000 Growth Index Jun 26
IDEAYA Biosciences, Inc. Appoints Catherine Mackey to its Board of Directors Apr 07
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 16
IDEAYA Biosciences, Inc. Advances First-in-Class PARG Development Candidate, IDE161, into IND-Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License Feb 01
IDEAYA Biosciences, Inc. Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma Dec 08
Director Yujiro Hata has joined 3rd company board Aug 24
IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort May 11
New 90-day high: €17.80 Mar 10
IDEAYA Biosciences, Inc. Appoints Susan L. Kelley to its Board of Directors Feb 18
New 90-day high: €16.40 Feb 10 IDEAYA Biosciences, Inc. Announces Appointment of Matthew Maurer as Head of Clinical Oncology and Medical Affairs
New 90-day high: €16.30 Jan 21
Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry Jan 20
IDEAYA Biosciences, Inc. Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA Jan 12
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor Jan 06
New 90-day low: €10.10 Dec 31
Nasdaq Biotechnology Index Selects IDEAYA Biosciences, Inc Dec 15
New 90-day high: €12.70 Dec 08
IDEAYA Biosciences, Inc. and Pfizer Inc. Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations Sep 26
IDEAYA Biosciences, Inc. Names Garret Hampton to the Nominating and Corporate Governance Committee Sep 17
IDEAYA Biosciences, Inc. announced that it has received $19.999995 million in funding from Glaxosmithkline Intellectual Property (No.4) Limited Aug 06 Shareholder Returns 30J DE Biotechs DE Market 7D 0% -2.9% -2.6% 1Y -21.2% -14.7% 6.9%
See full shareholder returns
Return vs Market: 30J underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is 30J's price volatile compared to industry and market? 30J volatility 30J Average Weekly Movement 7.2% Biotechs Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 30J's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 30J's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform.
Show more IDEAYA Biosciences, Inc. Fundamentals Summary How do IDEAYA Biosciences's earnings and revenue compare to its market cap? 30J fundamental statistics Market cap €2.12b Earnings (TTM ) -€170.71m Revenue (TTM ) €3.76m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 30J income statement (TTM ) Revenue US$3.92m Cost of Revenue US$193.26m Gross Profit -US$189.34m Other Expenses -US$11.22m Earnings -US$178.12m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.06 Gross Margin -4,827.59% Net Profit Margin -4,541.56% Debt/Equity Ratio 0%
How did 30J perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 03:23 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources IDEAYA Biosciences, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Madhu Kumar Baird Zhiqiang Shu Berenberg Justin Zelin BTIG
Show 22 more analysts 
